09:00

Opening remarks

Ahmed Allehebi

09:10

1^st Line Options of EGFR Positive Mets NSCLC (exon 19del , exon 21 (L858R) & 20)

Waleed Alghareeb

09:30

2^nd Line Options of EGFR Positive Mets NSCLC

Samah Alrehaily

09:50

Optionsin 1^st and Lines of ALK-1 Positive Mets NSCLC

Marwan Al Hejili

10:10

Optionsin ROS-1 , RET , RAS & MET-14 Skipping Positive Mets NSCLC

Ahmed Allehebi

10:30

Is there a Role of Immunotherapy in Driver’s Positive Mets NSCL

Hamed Al Husaini

10:50

Panel Discussion Q&A

11:00

Industrial Symposia

13:30

Role of MDT in the Management of NSCLC

Mervat Mahrous

13:50

Updates to the Role of Durvalumab After CCRT

Ahmed Allehebi

14:10

Radiation Therapy in Stage III NSCLC

Ameen Al-Omair

14:30

Optimizing Treatment Decisions in Stage III NSCLC

Turki Al Faye

14:50

Panel Discussion Q&A

15:30

Role of Adjuvant TKI in Early NSCLC

Turki Al Faye

15:50

Role of Immunotherapy in Early NSCLC

Ahmed Refae

16:10

Surgical Approach in Case of N2 Disease (NSCLC)

Ahmed Jamjoom

16:30

New Data for Neoadjuvant options in NSCLC

Shadi Alkhayyat

16:50

Panel Discussion Q&A

17:00

Industrial Symposium